查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067746

全球生物標記發現外包服務市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Biomarker Discovery Outsourcing Services Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 286 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球生物標記發現外包服務市場預計將從2025年的178.4億美元成長至2034年的891.9億美元，2026年至2034年的複合年成長率（CAGR）為19.58%。該市場正經歷強勁成長，主要得益於對精準醫療、藥物研發和先進診斷解決方案日益成長的需求。生物標記發現外包服務幫助製藥公司、生技公司和研究機構識別生物標記物，從而支持疾病檢測、治療方法選擇和治療效果監測。基因組學、蛋白質組學和個人化醫療領域的投資不斷增加，正在推動市場擴張。各機構擴大將生物標記研究活動外包，以利用專家知識、先進技術和經濟高效的開發流程。

癌症、心血管疾病和神經系統疾病等慢性病的日益普及顯著推動了基於生物標記的研究需求。分子生物學、人工智慧和高通量篩檢技術的進步正在加速生物標記的識別和檢驗。藥廠正利用外包服務來簡化臨床試驗流程，提高藥物研發的成功率。此外，研究機構與合約研究組織（CRO）之間合作的加強也促進了市場成長。

隨著精準醫療持續變革醫療服務模式，前景依然十分樂觀。多體學研究和數據分析領域的新興技術有望提升生物標記發現能力。對個人化醫療和伴隨診斷的投入增加將創造更多成長機會。隨著醫療系統日益重視標靶治療和疾病早期檢測，生物標記發現外包服務市場預計將持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球生物標記發現外包服務市場：按類型分類

  • 市場分析、洞察與預測
  • 預測性生物標記
  • 預後生物標記
  • 安全生物標記
  • 替代終點
  • 其他類型

第5章 全球生物標記發現外包服務市場：依服務類型分類

  • 市場分析、洞察與預測
  • 基因組學和生物標記服務
  • 蛋白質體學生物標記服務
  • 生物資訊學和生物標記服務
  • 其他生物標記服務

第6章 全球生物標記發現外包服務市場：依治療領域分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 自體免疫疾病
  • 其他治療領域

第7章 全球生物標記發現外包服務市場：依最終用途分類

  • 市場分析、洞察與預測
  • 製藥公司
  • 生技公司
  • 其他最終用戶

第8章 全球生物標記發現外包服務市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Charles River Laboratories International Inc
    • LabCorp（Laboratory Corporation Of America Holdings）
    • Eurofins Scientific
    • ICON Plc
    • Parexel International Corporation
    • Evotec SE
    • Crown Bioscience
    • Bio-Rad Laboratories
    • Frontage Laboratories Inc
    • Almac Group Limited
    • Sino Biological
    • REPROCELL Inc
    • Selvita SA
    • Proteome Sciences Plc
    • Celerion
簡介目錄
Product Code: VMR112118464

The global biomarker discovery outsourcing services market size is expected to reach USD 89.19 Billion in 2034 from USD 17.84 Billion in 2025, growing at a CAGR of 19.58 during 2026-2034.This market is experiencing strong growth due to increasing demand for precision medicine, drug development, and advanced diagnostic solutions. Biomarker discovery outsourcing services help pharmaceutical, biotechnology, and research organizations identify biological indicators that support disease detection, treatment selection, and therapeutic monitoring. Rising investments in genomics, proteomics, and personalized healthcare are driving market expansion. Organizations are increasingly outsourcing biomarker research activities to access specialized expertise, advanced technologies, and cost-efficient development processes.

The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is creating substantial demand for biomarker-based research. Advances in molecular biology, artificial intelligence, and high-throughput screening technologies are accelerating biomarker identification and validation. Pharmaceutical companies are utilizing outsourcing services to streamline clinical trials and improve drug development success rates. Additionally, increasing collaboration between research institutions and contract research organizations is supporting market growth.

Future prospects remain highly favorable as precision medicine continues transforming healthcare delivery. Emerging technologies in multi-omics research and data analytics are expected to enhance biomarker discovery capabilities. Expanding investments in personalized therapeutics and companion diagnostics will create additional growth opportunities. As healthcare systems increasingly focus on targeted treatments and early disease detection, the biomarker discovery outsourcing services market is projected to experience sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Safety Biomarkers
  • Surrogate Endpoints
  • Other Types

By Service

  • Genomics Biomarker Services
  • Proteomics Biomarker Services
  • Bioinformatics Biomarker Services
  • Other Biomarker Services

By Therapeutic Area

  • Oncology
  • Cardiology
  • Neurology
  • Autoimmune Diseases
  • Other Therapeutic Areas

By End Use

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Other End Users

COMPANIES PROFILED

  • Charles River Laboratories International Inc., LabCorp (Laboratory Corporation of, America Holdings), Eurofins Scientific, ICON plc, Parexel International Corporation, Evotec SE, Crown Bioscience, Bio-Rad Laboratories, Frontage Laboratories Inc., Almac Group Limited, Sino Biological, REPROCELL Inc., Selvita S.A., Proteome Sciences plc, Celerion

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Prognostic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Safety Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Surrogate Endpoints Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES MARKET: BY SERVICE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Service
  • 5.2. Genomics Biomarker Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Proteomics Biomarker Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Bioinformatics Biomarker Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other Biomarker Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Other Therapeutic Areas Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES MARKET: BY END USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End Use
  • 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type
    • 8.2.2 By Service
    • 8.2.3 By Therapeutic Area
    • 8.2.4 By End Use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type
    • 8.3.2 By Service
    • 8.3.3 By Therapeutic Area
    • 8.3.4 By End Use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type
    • 8.4.2 By Service
    • 8.4.3 By Therapeutic Area
    • 8.4.4 By End Use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type
    • 8.5.2 By Service
    • 8.5.3 By Therapeutic Area
    • 8.5.4 By End Use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type
    • 8.6.2 By Service
    • 8.6.3 By Therapeutic Area
    • 8.6.4 By End Use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOMARKER DISCOVERY OUTSOURCING SERVICES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Charles River Laboratories International Inc
    • 10.2.2 LabCorp (Laboratory Corporation Of America Holdings)
    • 10.2.3 Eurofins Scientific
    • 10.2.4 ICON Plc
    • 10.2.5 Parexel International Corporation
    • 10.2.6 Evotec SE
    • 10.2.7 Crown Bioscience
    • 10.2.8 Bio-Rad Laboratories
    • 10.2.9 Frontage Laboratories Inc
    • 10.2.10 Almac Group Limited
    • 10.2.11 Sino Biological
    • 10.2.12 REPROCELL Inc
    • 10.2.13 Selvita S.A
    • 10.2.14 Proteome Sciences Plc
    • 10.2.15 Celerion